Literature DB >> 9682352

Supplementation of conventional influenza A vaccine with purified viral neuraminidase results in a balanced and broadened immune response.

B E Johansson1, J T Matthews, E D Kilbourne.   

Abstract

Influenza virus neuraminidase was chromatographically extracted from A/Johannesburg/33/94 (H3N2) and used to supplement conventional monovalent H3JHN2JH inactivated influenza vaccine. Immunization of mice with this preparation resulted in high titers of antibodies to both hemagglutinin (HA) and neuraminidase (NA) equivalent for each antigen to titers in animals immunized with either antigen alone. Homotypic infection was suppressed and greater reduction in viral replication was observed following heterotypic infectious challenge than was observed following the non-supplemented vaccine. There was no evidence of suppression of the immune response to the HA despite the presence of high amounts of NA in the vaccine. Supplementation of conventional inactivated influenza vaccine with NA takes advantage of the equivalent immunogenicity of dissociated HA and NA, to produce a more balanced immune response to both surface antigens, without the antigenic competition tht occurs after immunization with conventional vaccine or infection. These studies in a mouse model system suggest that supplementation of current inactivated influenza vaccines offers the prospect of improved immunization of humans against influenza.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9682352     DOI: 10.1016/s0264-410x(97)00279-x

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  41 in total

1.  A human immunodeficiency virus prime-boost immunization regimen in humans induces antibodies that show interclade cross-reactivity and neutralize several X4-, R5-, and dualtropic clade B and C primary isolates.

Authors:  F Verrier; S Burda; R Belshe; A M Duliege; J L Excler; M Klein; S Zolla-Pazner
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

2.  Neuraminidase, the Forgotten Surface Antigen, Emerges as an Influenza Vaccine Target for Broadened Protection.

Authors:  Maryna C Eichelberger; Arnold S Monto
Journal:  J Infect Dis       Date:  2019-04-08       Impact factor: 5.226

Review 3.  Current research on influenza and other respiratory viruses: II international symposium.

Authors:  F M Munoz; G J Galasso; J M Gwaltney; F G Hayden; B Murphy; R Webster; P Wright; R B Couch
Journal:  Antiviral Res       Date:  2000-05       Impact factor: 5.970

Review 4.  Contribution of antibody production against neuraminidase to the protection afforded by influenza vaccines.

Authors:  Glendie Marcelin; Matthew R Sandbulte; Richard J Webby
Journal:  Rev Med Virol       Date:  2012-03-22       Impact factor: 6.989

5.  Neuraminidase-based recombinant virus-like particles protect against lethal avian influenza A(H5N1) virus infection in ferrets.

Authors:  Gale E Smith; Xiangjie Sun; Yaohui Bai; Ye V Liu; Michael J Massare; Melissa B Pearce; Jessica A Belser; Taronna R Maines; Hannah M Creager; Gregory M Glenn; David Flyer; Peter Pushko; Min Z Levine; Terrence M Tumpey
Journal:  Virology       Date:  2017-06-16       Impact factor: 3.616

6.  Recombinant soluble, multimeric HA and NA exhibit distinctive types of protection against pandemic swine-origin 2009 A(H1N1) influenza virus infection in ferrets.

Authors:  Berend Jan Bosch; Rogier Bodewes; Robert P de Vries; Joost H C M Kreijtz; Willem Bartelink; Geert van Amerongen; Guus F Rimmelzwaan; Cornelis A M de Haan; Albert D M E Osterhaus; Peter J M Rottier
Journal:  J Virol       Date:  2010-08-04       Impact factor: 5.103

7.  Neuraminidase-Inhibiting Antibody Titers Correlate with Protection from Heterologous Influenza Virus Strains of the Same Neuraminidase Subtype.

Authors:  Lisa Walz; Sarah-Katharina Kays; Gert Zimmer; Veronika von Messling
Journal:  J Virol       Date:  2018-08-16       Impact factor: 5.103

8.  Extending the Stalk Enhances Immunogenicity of the Influenza Virus Neuraminidase.

Authors:  Felix Broecker; Allen Zheng; Nungruthai Suntronwong; Weina Sun; Mark J Bailey; Florian Krammer; Peter Palese
Journal:  J Virol       Date:  2019-08-28       Impact factor: 5.103

Review 9.  Bench-to-bedside review: vaccine protection strategies during pandemic flu outbreaks.

Authors:  Joel V Chua; Wilbur H Chen
Journal:  Crit Care       Date:  2010-04-16       Impact factor: 9.097

Review 10.  Virus-like particles as universal influenza vaccines.

Authors:  Sang-Moo Kang; Min-Chul Kim; Richard W Compans
Journal:  Expert Rev Vaccines       Date:  2012-08       Impact factor: 5.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.